A Phase 1/2 Study of Copanlisib and Venetoclax in Patients With Relapsed or Refractory Mantle Cell Lymphoma
Latest Information Update: 11 Jun 2024
At a glance
- Drugs Copanlisib (Primary) ; Venetoclax (Primary)
- Indications Mantle-cell lymphoma
- Focus Adverse reactions; Therapeutic Use
- 03 Jun 2024 Status changed from suspended to active, no longer recruiting.
- 11 Dec 2023 Planned End Date changed from 31 Dec 2023 to 23 Nov 2024.
- 11 Dec 2023 Planned primary completion date changed from 31 Dec 2023 to 23 Nov 2024.